Last reviewed · How we verify

Inhibition of lactation procedure — Treatment Landscape & Competitive Intelligence

Inhibition of lactation procedure (disease) competitive landscape: 3 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

3 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Inhibition of lactation procedure, deduplicated by molecule. See the full disease page for line-of-therapy detail.

DrugGenericSponsorClassTargetLine of therapyFirst approval
Testred METHYLTESTOSTERONE Bausch Health Androgen [EPC] Androgen receptor 1973-01-01
Androgel TESTOSTERONE Besins Hlthcare Androgen [EPC] Androgen receptor 1972-01-01
Testosteron Testosteron Gulhane School of Medicine Corticosteroid-binding globulin, Alpha-synuclein, Lanosterol 14-alpha demethylase

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

  1. Bausch Health · 1 drug in Inhibition of lactation procedure
  2. Besins Hlthcare · 1 drug in Inhibition of lactation procedure
  3. Gulhane School of Medicine · 1 drug in Inhibition of lactation procedure

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Inhibition of lactation procedure:

Cite this brief

Drug Landscape (2026). Inhibition of lactation procedure — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/inhibition-of-lactation-procedure. Accessed 2026-06-10.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing